BRAF and melanoma: The combination of vemurafenib with ipatasertib had no effect beyond that of ipatasertib alone on the two BRAF V600E mutant colon carcinoma lines 282377-053-R-J1 and 762968-020-R-J2 or the BRAF wildtype melanoma line SK-MEL-2, except at the very highest concentrations of the BRAF inhibitors.